Patents Assigned to Pharming
-
Publication number: 20230235023Abstract: The claimed invention relates to treatment of virus-related respiratory distress, particularly methods for treating such distress by administering a complement inhibitor. The types of virus-related respiratory distress that can be treated according to the invention include acute respiratory distress syndrome and related phenomena, and can be linked to infection by a coronavirus such as SARS-CoV-2. The invention includes administering complement inhibitor, which can be recombinant or purified C1 inhibitor, and administering complement inhibitor in combination with other therapeutics.Type: ApplicationFiled: April 19, 2021Publication date: July 27, 2023Applicant: Pharming Intellectual Property B.V.Inventors: Bruno Giannetti, Anurag Relan, Juergen Ulrich Schaale-Maass
-
Publication number: 20210324107Abstract: The claimed invention relates to treatment of virus-related respiratory distress, particularly methods for treating such distress by administering a complement inhibitor. The types of virus-related respiratory distress that can be treated according to the invention include acute respiratory distress syndrome and related phenomena, and can be linked to infection by a coronavirus such as SARS-CoV-2. The invention includes administering complement inhibitor, which can be recombinant or purified Cl inhibitor, and administering complement inhibitor in combination with other therapeutics.Type: ApplicationFiled: April 19, 2021Publication date: October 21, 2021Applicant: Pharming Intellectual Property B.V.Inventors: Bruno GIANNETTI, Jürgen SCHAALE, Anurag RELAN
-
Publication number: 20200390872Abstract: The present invention relates to the field of medicine, specifically to the prevention and treatment of pre-eclampsia.Type: ApplicationFiled: February 28, 2019Publication date: December 17, 2020Applicant: Pharming Intellectual Property B.V.Inventors: Sijmen de Vries, Bruno Giannetti
-
Patent number: 9546381Abstract: The invention relates to the production of recombinant human fibrinogen (rhFib) in the milk of transgenic mammalian animals. This production and subsequent purification process is generally hampered by the occurrence of so-called ‘clots’ and ‘flakes’ in the milk which, in severe cases, may prevent the cow from being milked at all, resulting in a halt of lactation. These clots and flakes occur because of the expression of the fibrinogen protein, which is a factor that is normally involved in blood clotting. The invention relates to solving this milk clotting problem by treating the (lactating) animals with anticoagulants such as coumarins. A preferred anticoagulant that is used in the methods of the present invention is warfarin.Type: GrantFiled: March 11, 2011Date of Patent: January 17, 2017Assignee: PHARMING INTELLECTUAL PROPERTY BVInventors: Kathryn Margaret Nelson, Michael William Mosesson, Anthony Pusateri, Erik Jordahl Forsberg
-
Patent number: 9408366Abstract: A milking device includes a vessel and cover plate. The vessel and the cover plate form a sealed volume that is internally divided into a collecting chamber, a vacuum chamber and an air intake chamber. The collecting chamber is arranged between the vacuum chamber and the air intake chamber. The vessel has a first internal wall that separates the collecting chamber from the air intake chamber, with a first passage between the collecting chamber and the air intake chamber arranged at the first internal wall. The vessel has a second internal wall that separates the collecting chamber from the vacuum chamber, with a second passage between the collecting chamber and the vacuum chamber arranged at the second internal wall.Type: GrantFiled: January 19, 2012Date of Patent: August 9, 2016Assignee: PHARMING INTELLECTUAL PROPERTY BVInventors: Mourad Salaheddine, Marc Peter Elvira Maria Klyutmans, Pieter Cornelis Johannes Maria Streng
-
Patent number: 9211318Abstract: The present invention relates to the therapeutic and prophylactic use of C1 inhibitor for preventing, reducing and treating ischemia and reperfusion injury. The C1 inhibitor of the present invention is still therapeutically effective when administered after an ischemic period and reperfusion and therefore particularly useful for unforeseen occurrences of ischemic reperfusion such as e.g. a stroke.Type: GrantFiled: February 25, 2013Date of Patent: December 15, 2015Assignee: PHARMING INTELLECTUAL PROPERTY B.V.Inventors: Maurice Mannesse, Johannes Henricus Nuijens, Frank Pieper, Maria Grazia De Simoni, Gijsbertus Johannes Ziere
-
Publication number: 20140373786Abstract: A milking device includes a vessel and cover plate. The vessel and the cover plate form a sealed volume that is internally divided into a collecting chamber, a vacuum chamber and an air intake chamber. The collecting chamber is arranged between the vacuum chamber and the air intake chamber. The vessel has a first internal wall that separates the collecting chamber from the air intake chamber, with a first passage between the collecting chamber and the air intake chamber arranged at the first internal wall. The vessel has a second internal wall that separates the collecting chamber from the vacuum chamber, with a second passage between the collecting chamber and the vacuum chamber arranged at the second internal wall.Type: ApplicationFiled: January 19, 2012Publication date: December 25, 2014Applicant: Pharming Intellectual Property BVInventors: Mourad Salaheddine, Marc Peter Elvira Maria Kluytmans, Pieter Cornelis Johannes Maria Streng
-
Publication number: 20130244941Abstract: The present invention relates to the therapeutic and prophylactic use of C1 inhibitor for preventing, reducing and treating ischemia and reperfusion injury. The C1 inhibitor of the present invention is still therapeutically effective when administered after an ischemic period and reperfusion and therefore particularly useful for unforeseen occurrences of ischemic reperfusion such as e.g. a stroke.Type: ApplicationFiled: February 25, 2013Publication date: September 19, 2013Applicant: PHARMING INTELLECTUAL PROPERTY B.V.Inventors: Maurice Mannesse, Johannes Henricus Nuijens, Frank Pieper, Maria Grazia De Simoni, Gijsbertus Johannes Ziere
-
Patent number: 8415288Abstract: The present invention relates to the therapeutic and prophylactic use of C1 inhibitor for preventing, reducing and treating ischemia and reperfusion injury. The C1 inhibitor of the present invention is still therapeutically effective when administered after an ischemic period and reperfusion and therefore particularly useful for unforeseen occurrences of ischemic reperfusion such as e.g. a stroke.Type: GrantFiled: October 11, 2011Date of Patent: April 9, 2013Assignee: Pharming Intellectual Property B.V.Inventors: Maurice Mannesse, Johannes Henricus Nuijens, Frank Pieper, Maria Grazia De Simoni, Gijsbertus Johannes Ziere
-
Publication number: 20130053546Abstract: The invention relates to the production of recombinant human fibrinogen (rhFib) in the milk of transgenic mammalian animals. This production and subsequent purification process is generally hampered by the occurrence of so-called ‘clots’ and ‘flakes’ in the milk which, in severe cases, may prevent the cow from being milked at all, resulting in a halt of lactation. These clots and flakes occur because of the expression of the fibrinogen protein, which is a factor that is normally involved in blood clotting. The invention relates to solving this milk clotting problem by treating the (lactating) animals with anticoagulants such as coumarins. A preferred anticoagulant that is used in the methods of the present invention is warfarin.Type: ApplicationFiled: March 11, 2011Publication date: February 28, 2013Applicant: PHARMING INTELLECTUAL PROPERTY BVInventors: Kathryn Margaret Nelson, Michael William Mosesson, Anthony Pusateri, Erik Jordahl Forsberg
-
Publication number: 20120088728Abstract: The present invention relates to the therapeutic and prophylactic use of C1 inhibitor for preventing, reducing and treating ischemia and reperfusion injury. The C1 inhibitor of the present invention is still therapeutically effective when administered after an ischemic period and reperfusion and therefore particularly useful for unforeseen occurrences of ischemic reperfusion such as e.g. a stroke.Type: ApplicationFiled: October 11, 2011Publication date: April 12, 2012Applicant: PHARMING INTELLECTUAL PROPERTY B.V.Inventors: Maurice Mannesse, Johannes Henricus Nuijens, Frank Pieper, Maria Grazia De Simoni, Gijsbertus Johannes Ziere
-
Patent number: 8071532Abstract: The present invention relates to the therapeutic and prophylactic use of C1 inhibitor for preventing, reducing and treating ischemia and reperfusion injury. The C1 inhibitor of the present invention is still therapeutically effective when administered after an ischemic period and reperfusion and therefore particularly useful for unforeseen occurrences of ischemic reperfusion such as e.g. a stroke.Type: GrantFiled: December 19, 2006Date of Patent: December 6, 2011Assignee: Pharming Intellectual Property B.V.Inventors: Maurice Mannesse, Johannes Henricus Nuijens, Frank Pieper, Maria Grazia De Simoni, Gijsbertus Johannes Ziere
-
Publication number: 20110263503Abstract: The invention provides low-half life fibrinogen as a result of recombinant expression or enzymatic and chemical removal. The low-half life fibrinogen is useful in treating or effecting prophylaxis of bleeding particularly in situations of an acute nature in which a high initial dose and rapid decline to normal or below normal levels is desirable.Type: ApplicationFiled: April 29, 2009Publication date: October 27, 2011Applicant: Pharming Intellectual Property B.V.Inventors: Frank Pieper, Anurag Relan, Erik Jordahl Forsberg
-
Publication number: 20100305039Abstract: The invention provides transgenic nonhuman mammals capable secreting exogenous procollagen or collagen into their milk. The mammals are healthy and capable of producing procollagen or collagen at high levels, usually in trimeric form. Suitable transgenes for incorporation into the mammals are also provided.Type: ApplicationFiled: November 10, 2008Publication date: December 2, 2010Applicants: Pharming Intellectual Property B.V., Cohesion Technologies, Inc.Inventors: Costas N. Karatzas, Frank Pieper, Ineke De Wit, Richard Berg, Gerard Platenburg, Paul David Toman
-
Publication number: 20100143490Abstract: The present invention provides a composite material comprising lactoferrin and a bioactive glass. The invention also relates to pharmaceutical compositions containing the composite material. Further aspects of the invention relate to the use of the composite material of the for treating a wound, treating or preventing bacterial or viral infections in a wound, preventing viral transmission, regenerating bone, treating osteoporosis, preventing or alleviating bleeding in a wound, sterilising a wound and/or controlling haemorrhaging.Type: ApplicationFiled: August 21, 2007Publication date: June 10, 2010Applicants: NOVA THERA LIMITED, PHARMING GROUP NVInventors: Gareth Roberts, Robert Daniels, Xiaobin Zhao, Ian Thompson
-
Publication number: 20100136131Abstract: The present invention provides a composite material comprising fibrinogen or fibrin, or a mixture thereof, and a bioactive glass. The invention also relates to wound dressings and pharmaceutical compositions containing the composite material. Further aspects of the invention relate to the use of the composite material of the for treating a wound, treating or preventing bacterial infections in a wound, preventing or alleviating bleeding in a wound, sterilising a wound, controlling haemorrhaging, increasing the rate of coagulation of blood and/or activating a coagulation system in a wound.Type: ApplicationFiled: August 21, 2007Publication date: June 3, 2010Applicants: NOVATHERMA LIMITED, PHARMING GROUP NVInventors: Gareth Roberts, Robert Daniels, Xiaobin Zhao, Ian Thompson
-
Patent number: 7544853Abstract: The present invention relates to the use of a C1 inhibitor (C1INH) with shorter half-life than plasma-derived C1INH for the preparation of a medicament for the transient treatment of an individual. It relates to both therapeutic and prophylactic treatment. The method of the invention allows for the administration of C1INH at certain therapeutic levels for a concise pre-determined time span. Pharmaceutical compositions based on C1INH with shorter half-lives may be used both in situations where transient treatment is merely and advantage. The advantage of the use according to the invention is that an individual is not exposed to C1INH for longer than required, since the levels of the C1INH more rapidly subsides after administration has stopped. In contrast, levels of plasma-derived C1INH would remain elevated for a prolonged period of time.Type: GrantFiled: May 14, 2004Date of Patent: June 9, 2009Assignee: Pharming Intellectual Property B.V.Inventor: Johannes Henricus Nuijens
-
Publication number: 20080305993Abstract: The present invention relates to the therapeutic and prophylactic use of C1 inhibitor for preventing, reducing and treating ischemia and reperfusion injury. The C1 inhibitor of the present invention is still therapeutically effective when administered after an ischemic period and reperfusion and therefore particularly useful for unforeseen occurrences of ischemic reperfusion such as e.g. a stroke.Type: ApplicationFiled: December 19, 2006Publication date: December 11, 2008Applicant: Pharming Intellectual Property B.V.Inventors: Maurice Mannesse, Johannes Henricus Nuijens, Frank Pieper, Maria Grazia De Simoni, Gijsbertus Johannes Ziere
-
Patent number: RE42704Abstract: Materials and methods for producing fibrinogen in transgenic non-human mammals are disclosed. DNA segments encoding A?, B? and ? chains of fibrinogen are introduced into the germ line of a non-human mammal, and the mammal or its female progeny produces milk containing fibrinogen expressed from the introduced DNA segments. Non-human mammalian embryos and transgenic non-human mammals carrying DNA segments encoding heterologous fibrinogen polypeptide chains are also disclosed.Type: GrantFiled: January 15, 1999Date of Patent: September 13, 2011Assignee: Pharming Intellectual Property B.V.Inventors: Donna E. Prunkard, Donald C. Foster
-
Patent number: RE43691Abstract: The present invention relates to the use of a C1 inhibitor (C1INH) with shorter half-life than plasma-derived C1INH for the preparation of a medicament for the transient treatment of an individual. It relates to both therapeutic and prophylactic treatment. The method of the invention allows for the administration of C1INH at certain therapeutic levels for a concise pre-determined time span. Pharmaceutical compositions based on C1INH with shorter half-lives may be used both in situations where transient treatment is merely and advantage. The advantage of the use according to the invention is that an individual is not exposed to C1INH for longer than required, since the levels of the C1INH more rapidly subsides after administration has stopped. In contrast, levels of plasma-derived C1INH would remain elevated for a prolonged period of time.Type: GrantFiled: May 14, 2004Date of Patent: September 25, 2012Assignee: Pharming Intellectual Property B.V.Inventor: Johannes Henricus Nuijens